ProfileGDS5678 / 1448521_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 83% 82% 83% 83% 83% 82% 82% 83% 84% 83% 82% 82% 84% 83% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.013483
GSM967853U87-EV human glioblastoma xenograft - Control 26.044882
GSM967854U87-EV human glioblastoma xenograft - Control 36.0173183
GSM967855U87-EV human glioblastoma xenograft - Control 46.17383
GSM967856U87-EV human glioblastoma xenograft - Control 56.0868483
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.7730682
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.7908382
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.9920383
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.205284
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.0990483
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.975782
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.9902482
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.1475884
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.0059983